Toward a more informative multimodal data analysis of the pediatric AML transcriptome

Jenea I. Adams


2nd year Ph.D. Student (GCB)

Xing Lab Roundtable

Monday, March12th, 2021

Acute myeloid leukemia (AML) is the most fatal of childhood cancers with no good treatments


- Caused by accumulation of immature myeloid cells in bone marrow
- Affects 25% of children with leukemia
- Chemotherapy for acute lymphoblastic leukemia (ALL) is generally successful
 - Kills healthy and aberrant B-cells → stable prognosis



Current treatment strategies for pediatric AML are based adult genomes/transcriptomes

- Mean age of AML onset is 45 years
- "Pediatric" considered 0 years to ~30 years old
- Age-specific genomic signatures have been linked to prognosis (Bullinger et al., 2017)
- Hematopoietic expansion has agespecific regulation (Bullinger et al., 2017)


What about splicing?



Alternative splicing and correlated molecular pathways could help to better distinguish pediatric vs adult AML

Aberrant splicing occurs in AML **Splicing** Alternative signatures exist splicing is that correlate with common in pediatric AML cancer subtypes Splicing Hypothesis: diversifies the Gene expression New agesignatures genome and specific, downstream correlate with multimodal proteomic AML prognosis insights products

PEGASAS correlates gene ontology and alternative splicing events



Hypothesis: Alternative splicing and correlated molecular pathways could play important roles in distinguishing pediatric vs adult AML

Aim 1


Improve analysis of splicing in large heterogeneous RNA-seq datasets

Aim 2

Discover age-specific, pathway-dependent alternative splicing patterns in pediatric AML RNA-seq data

<u>Aim 1:</u> Improve analysis of splicing in large heterogenous RNA-seq datasets

- PEGASAS lacks an approach to make batch effect-informed correlations
- Capture and use expression heterogeneity to mitigate batch effects
 → Surrogate variable analysis (SVA)
- Using SVA could improve reproducibility and downstream accuracy
- Approach
 - Compare pathway-relevant exons detected with/without SVA



<u>Aim 2:</u> Discover age-specific, pathway-dependent alternative splicing patterns in pediatric AML RNA-seq data

